Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Sesen Bio Inc (SESN)

Sesen Bio Inc (SESN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 127,956
  • Shares Outstanding, K 203,492
  • Annual Sales, $ 40,000 K
  • Annual Income, $ -19,880 K
  • 60-Month Beta 0.83
  • Price/Sales 2.98
  • Price/Cash Flow 3.39
  • Price/Book 0.81
Trade SESN with:
  • Price/Earnings ttm 11.72
  • Earnings Per Share ttm 0.11
  • Most Recent Earnings $-0.04 on 02/28/23
  • Latest Earnings Date 02/27/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5250 +19.77%
on 02/13/23
0.6449 -2.50%
on 03/02/23
+0.0288 (+4.80%)
since 02/07/23
3-Month
0.4500 +39.73%
on 12/19/22
0.6500 -3.26%
on 01/18/23
+0.0963 (+18.08%)
since 12/07/22
52-Week
0.3650 +72.27%
on 09/27/22
0.9650 -34.84%
on 07/14/22
+0.0314 (+5.26%)
since 03/07/22

Most Recent Stories

More News
Sesen Bio Stockholders Approve Merger with Carisma Therapeutics

Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that its stockholders have voted to approve all proposals, including the pending merger with Carisma Therapeutics...

SESN : 12.5760 (+7.29%)
Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results

Sesen Bio (Nasdaq: SESN ) today reported operating results for the fourth quarter and full year ended December 31, 2022, and provided a business update.

SESN : 12.5760 (+7.29%)
SHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and SHBI Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

SESN : 12.5760 (+7.29%)
MLVF : 16.97 (+0.24%)
VLON : 12.0000 (-13.04%)
SHBI : 10.16 (+0.79%)
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With Carisma

Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that leading independent proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) recommends that stockholders vote...

SESN : 12.5760 (+7.29%)
Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting

Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that Institutional Shareholder Services (“ISS”) recommends that stockholders vote “FOR” all proposals, including...

SESN : 12.5760 (+7.29%)
Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger

Sesen Bio, Inc. (Nasdaq: SESN) today announced that members of its management team will host a fireside chat with members of the Carisma Therapeutics Inc. (“Carisma”) management team on Tuesday, February...

SESN : 12.5760 (+7.29%)
SHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and APEN Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

SESN : 12.5760 (+7.29%)
MLVF : 16.97 (+0.24%)
VLON : 12.0000 (-13.04%)
APEN : 10.00 (+0.81%)
BML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics

Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that BML Investment Partners, L.P. (“BML”), one of Sesen Bio’s top stockholders, intends to vote all of its...

SESN : 12.5760 (+7.29%)
Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger

Sesen Bio, Inc. (Nasdaq: SESN) and Carisma Therapeutics Inc. (Carisma), a privately-held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today...

SESN : 12.5760 (+7.29%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SESN, LMST, SAL

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

SESN : 12.5760 (+7.29%)
LMST : 23.42 (-1.39%)
SAL : 27.88 (+1.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Sesen Bio Inc. is a late-stage company developing next-generation antibody-drug conjugate therapies for patients with cancer. The company's product portfolio includes Vicinium(TM) which is in its clinical trial, treats high-grade non-muscle invasive bladder cancer. Sesen Bio Inc., formerly known as Eleven...

See More

Key Turning Points

3rd Resistance Point 0.7072
2nd Resistance Point 0.6680
1st Resistance Point 0.6484
Last Price 12.5760
1st Support Level 0.5896
2nd Support Level 0.5504
3rd Support Level 0.5308

See More

Last Price 12.5760
52-Week High 0.9650
Fibonacci 61.8% 0.7358
Fibonacci 50% 0.6650
Fibonacci 38.2% 0.5942
52-Week Low 0.3650

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar